John McKune - Pulmonx Corp VP Controller
| LUNG Stock | USD 6.42 0.22 3.55% |
Insider
John McKune is VP Controller of Pulmonx Corp
| Age | 48 |
| Address | 700 Chesapeake Drive, Redwood City, CA, United States, 94063 |
| Phone | 650 364 0400 |
| Web | https://pulmonx.com |
John McKune Latest Insider Activity
Tracking and analyzing the buying and selling activities of John McKune against Pulmonx Corp stock is an integral part of due diligence when investing in Pulmonx Corp. John McKune insider activity provides valuable insight into whether Pulmonx Corp is net buyers or sellers over its current business cycle. Note, Pulmonx Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pulmonx Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John McKune over three months ago Acquisition by John McKune of 7233 shares of Pulmonx Corp subject to Rule 16b-3 | ||
John McKune over six months ago Disposition of 254 shares by John McKune of PulmonxCorp at 9.06 subject to Rule 16b-3 |
Pulmonx Corp Management Efficiency
The company has return on total asset (ROA) of (0.2004) % which means that it has lost $0.2004 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5199) %, meaning that it created substantial loss on money invested by shareholders. Pulmonx Corp's management efficiency ratios could be used to measure how well Pulmonx Corp manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.36. The current Return On Capital Employed is estimated to decrease to -0.42. At this time, Pulmonx Corp's Asset Turnover is most likely to slightly decrease in the upcoming years.Similar Executives
| Showing other executives | INSIDER Age | ||
| Bradley JD | Axogen Inc | 54 | |
| Mark Saxton | Neuropace | 59 | |
| Rebecca Kuhn | Neuropace | 63 | |
| Gregory Davault | Axogen Inc | 56 | |
| Mark CPA | Treace Medical Concepts | 54 | |
| Kristin Caltrider | Inogen Inc | 56 | |
| Ehab Esmail | Orthofix Medical | 52 | |
| Michael Hutchinson | LivaNova PLC | 53 | |
| Anshul Maheshwari | Si Bone | 44 | |
| Agnes Lee | Inogen Inc | N/A | |
| Andre Marquette | Neuropace | N/A | |
| Nabil Shabshab | Inogen Inc | 59 | |
| Joseph Powers | Si Bone | 64 | |
| Michael Favet | Neuropace | 54 | |
| John Treace | Treace Medical Concepts | 52 | |
| Jaime Frias | Treace Medical Concepts | 62 | |
| Matthew Pigeon | Inogen Inc | N/A | |
| Brad Nagel | Electromed | N/A | |
| Laverne Council | CONMED | 59 | |
| Matt Garner | Iradimed Co | N/A | |
| Chi Nguyen | Neuropace | 47 | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.2 |
Pulmonx Corp Leadership Team
Elected by the shareholders, the Pulmonx Corp's board of directors comprises two types of representatives: Pulmonx Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pulmonx. The board's role is to monitor Pulmonx Corp's management team and ensure that shareholders' interests are well served. Pulmonx Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pulmonx Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Williamson, President CEO | ||
| David Lehman, General Secretary | ||
| Geoffrey Rose, Chief Officer | ||
| Lauren Cristina, VP Adm | ||
| John McKune, VP Controller | ||
| Sri Radhakrishnan, Chief Officer | ||
| Mehul Joshi, Chief Officer | ||
| Jrme Erath, Senior Africa | ||
| Marcee Maroney, Vice Marketing | ||
| Derrick Sung, Chief Officer | ||
| Glendon French, President CEO | ||
| Sarah Huber, Vice Sales | ||
| Lisa Paul, Chief Officer | ||
| David JD, General Secretary |
Pulmonx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pulmonx Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.72) % | ||||
| Operating Margin | (0.69) % | ||||
| Current Valuation | 192.85 M | ||||
| Shares Outstanding | 39.49 M | ||||
| Shares Owned By Insiders | 5.16 % | ||||
| Shares Owned By Institutions | 94.90 % | ||||
| Number Of Shares Shorted | 986.14 K | ||||
| Price To Book | 2.61 X |
Currently Active Assets on Macroaxis
When determining whether Pulmonx Corp is a strong investment it is important to analyze Pulmonx Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmonx Corp's future performance. For an informed investment choice regarding Pulmonx Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pulmonx Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmonx Corp. If investors know Pulmonx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmonx Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Revenue Per Share 2.043 | Quarterly Revenue Growth 0.154 | Return On Assets (0.20) | Return On Equity (0.52) |
The market value of Pulmonx Corp is measured differently than its book value, which is the value of Pulmonx that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmonx Corp's value that differs from its market value or its book value, called intrinsic value, which is Pulmonx Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmonx Corp's market value can be influenced by many factors that don't directly affect Pulmonx Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmonx Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmonx Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmonx Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.